samedan logo

 
 
spacer
home > pmps > autumn 2003 > cryogenics leads the way in emissions control
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Cryogenics Leads the Way in Emissions Control

Emissions control has long been an important management issue for pharmaceutical manufacturers in Europe and beyond, but emerging legislation implemented throughout EU member states is forcing the industry to take a closer look at abatement technologies in search of solutions which will ensure compliance not just now, but in the future too.

Legislation puts Focus on Solvent Recovery

The manufacture of pharmaceutical products is reliant on a number of organic solvents, producing emissions in a number of process areas - from reactor vents to storage tanks and vacuum pumps. Dichloromethane, methanol, ethyl acetate, acetone, toluene, xylene, triethylamine, tetrahydrofurane, butyl acetate and isopropanol are among the VOCs regularly used by pharmaceutical manufacturers and legislation is limiting these emissions year on year. Industrial emissions to the atmosphere first became a focus of environmental regulation with the introduction of the Clean Air Act in 1993. Since then increasing concern about the effect of air pollutants on the environment has led to the development of the UK's National Air Quality Strategy, setting targets which are to be achieved by 2005.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Diana Raine, Business Manager for Cryogenics in Europe at Air Products

Diana Raine is Air Products' Business Manager for cryogenics in Europe and specialises in finding applications for cryogenic technology in modern industrial processes. She joined the company 12 years ago with a Masters in Chemical Engineering.

spacer
Diana Raine
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Coveris invests in clean energy from Swedish Wind Farm

Vienna, 30. January 2023; Coveris, a European leader in the packaging sector, signed a 10-year purchase agreement with Neoen, one of the world’s leading producers of exclusively renewable energy. Coveris is thus investing in green energy that meets the electricity needs of its European plants and will be generated by a future wind farm in Storbrännkullen, Sweden.
More info >>

White Papers

Driving ROI: The Case for Investing in Contract & Site Regulatory Document Management Services

DrugDev

With tight timelines and complicated regulatory documentation requirements, getting a clinical trial up and running quickly is easier said than done. Key milestones can be achieved only after the successful negotiation of clinical trial agreements and completion of essential regulatory documents. Many clinical trials are hindered by inefficient, labor-intensive processes. Prolonged, inefficient activation can hamper investigator satisfaction and, ultimately, have a negative bottom-line impact for sponsors and CROs. In addition, the Sunshine Act is heightening the importance of financial disclosure in clinical trials. Without a robust financial disclosure strategy, sponsors cannot ensure that physician self-reported financial disclosure data are aligned with the payment data being reported through the Sunshine Act, increasing financial and regulatory risk.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement